Leukemia

Increasing genetic complexity over time allows multiple myeloma to acquire drug resistance, but immu

Possible Role for Comprehensive Molecular Profiling–Based Treatment Selection in Newly Diagnosed AML, Study Suggests

By

This approach requires a team-coordinated effort by investigators, patients, and caregivers, as well as genomic and cytogenetic laboratories.

Ceritinib Demonstrates Strong Response in ALK-positive NSCLC

Features of Lung Cancer Treatment–Related AML

By

Andrea S. Blevins Primeau, PhD, MBA

Therapy-related AML after lung cancer is rare, but is associated with poor prognosis.

Predictors of Late Effects in Young AML Survivors Explored

Most common late effects were endocrine, cardiovascular, respiratory; likelihood of late effects up for those who underwent HSCT.

Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results

By

Susan Moench, PhD, PA-C

Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.

Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.

Ivosidenib Plus Azacitidine Well-Tolerated in Select Patients with Acute Myeloid Leukemia

By

Patricia Chaney

A phase 1b trial found ivosidenib with azacitidine well-tolerated in patients with AML who are ineligible for intensive chemotherapy.

Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.

Promising Results for Chemotherapy-Free Induction/Consolidation Therapy in Philadelphia-Positive ALL

By

Susan Moench, PhD, PA-C

Patients with Philadelphia chromosome-positive ALL were treated with dasatinib and blinatumomab during induction and consolidation therapy — without chemotherapy.

CTA asked Dr. Patnaik about the evolving understanding of CMML’s molecular underpinnings, diagnosis,

Relapse Risk Reduced in Acute Myeloid Leukemia With Recombinant Human Granulocyte Colony-Stimulating Factor, Decitabine

By

Patricia Chaney

Among patients with AML, maintenance therapy with rhG-CSF plus decitabine led to fewer relapses compared with patients who received no treatment after HSCT.

Anti-CD19 CAR T-Cell Therapy Effective in Relapsed/Refractory B-Cell Acute Lymphocytic Leukemia

By

Jonathan Goodman, MPhil

Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.

Interpreting PET scores according to established criteria is crucial for guiding treatment following initial chemotherapy in early-stage disease.

Survival Outcomes in Acute Myeloid Leukemia Associated With Measureable Residual Disease Status

By

Jonathan Goodman, MPhil

Among patients with acute myeloid leukemia, minimal residual disease-negativity may be linked to improved survival rates.

Some Patients With AML Secondary to MPN May Benefit From Venetoclax in Combination With a Hypomethylating Agent

By

Susan Moench, PhD, PA-C

Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.

Novel Prognostic Model Predictive of Survival in Ibrutinib-Treated Chronic Lymphocytic Leukemia

By

Jonathan Goodman, MPhil

Researchers evaluated and validated the effectiveness of a 4-factor prognostic model among patients with CLL treated with ibrutinib.

Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1

Real-World Benchmarks for Response to Second and Third FLT3 Inhibitor Exposure in FLT3-Mutated AML

By

Susan Moench, PhD, PA-C

Addition of midostaurin, a first-generation FLT3 inhibitor, to frontline induction therapy is currently a standard approach to the treatment of FLT3-mutated AML.

Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy

Unfitness Criteria Predict Early Mortality After Intensive Chemotherapy in Acute Myeloid Leukemia

By

Lauren Dembeck, PhD

The Ferrara criteria are widely used to identify patients with AML who are most suitable for intensive chemotherapy, though the accuracy is unknown.

FDA Grants Full Approval to Venclexta for Acute Myeloid Leukemia

By

Brian Park, PharmD

The full approval was based on efficacy and safety data from the phase 3 VIALE-A (M15-656) and VIALE-C (M16-043) studies.

A doctor sits at his desk, working hard.

British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia

By

Caleb Rans, PharmD

The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.

Chemotherapy for Relapsed or Refracted Acute Myeloid Leukemia Unresponsive Venetoclax Salvage Therapy

By

Patricia Chaney

Patients with relapsed/refractory AML who do not respond to venetoclax-based salvage therapy may have a response to intensified chemotherapy.

Managing adverse effects after starting a TKI can be challenging, and health care practitioners ofte

First-line Therapy Response vs Switching Treatments in Chronic Myeloid Leukemia

By

Patricia Chaney

CP-CML patients who remain on first-line TKI therapy have better clinical responses than patients who switch within the first 3 years.

Prostate cancer patients with high PSA anxiety, low health literacy who experience recurrence twice

Fixed-Duration Venetoclax Plus Rituximab Confers Benefit in Chronic Lymphocytic Leukemia

By

Patricia Chaney

Fixed-duration venetoclax plus rituximab provides sustained, durable response for patients with relapsed chronic lymphocytic leukemia.

Image of chronic lymphocytic leukemia cells

Patients With CML Continue to Be Prescribed Costly Second-Gen TKIs

By

Christina Bennett, MS

Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.

Factors Associated With Suicide in Leukemia Identified

Risk factors include male sex, older age at diagnosis, White race.

Combined Venetoclax, Obinutuzumab vs Chlorambucil, Obinutuzumab for Chronic Lymphocytic Leukemia

By

Jonathan Goodman, MPhil

Venetoclax plus obinutuzumab appears to yield good responses for a limited duration among patients with previously untreated CLL.

2020 Guidelines on Treating Acute Myeloid Leukemia in Older Adults

By

Rita Aghjayan

Recent guidelines have provided additional information on the treatment, management, and risk-stratifications of acute myeloid leukemia in older patients.

Sorafenib Maintenance Post Transplantation for FLT3-ITD Acute Myeloid Leukemia

By

Vicki Moore, PhD

Sorafenib maintenance showed positive relapse, survival, and safety outcomes for patients with FLT3-ITD acute myeloid leukemia after transplantation.

5-azacitidine may lead to sustained response in peripheral T-cell lymphoma.

Effects of 5-Azacitidine Dose Changes With Myelodysplastic Syndrome

By

Vicki Moore, PhD

For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.

The new type of adoptive cell therapy showed a response in 8 of 11 patients with hematologic malignancies in a clinical study.

Opposition to a European Patent for CAR-T Therapy: A Mechanism to Control High Drug Prices?

By

Susan Moench, PhD, PA-C

The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.

Triple Therapy for CLL Shows Promise in Phase 2 Trial

By

Caroline Seydel

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.

Venetoclax With 10-day Decitabine May Induce High Activity in High-Risk Acute Myeloid Leukemia

By

Patricia Chaney

Patients with newly diagnosed AML who are ineligible for intensive chemotherapy may benefit from a 10-day course of decitabine with venetoclax.

Venetoclax With a Hypomethylating Agent Effective in Treatment-Naive or Relapsed/Refractory Acute Myeloid Leukemia

By

Jonathan Goodman, MPhil

Regardless of genotype, venetoclax with a hypomethylating agent yields strong response and survival outcomes among patients with treatment-naive or R/R AML.

Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patient

Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors

By

Christina Bennett, MS

Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.

Alvocidib Receives Orphan Drug Designation for AML

Risk-Adapted Bendamustine and Rituximab: An Alternative for Older Individuals With CLL

By

Christina Bennett, MS

Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.

The ACS estimates that 18,960 new cases of chronic lymphocytic leukemia (CLL) will be diagnosed in t

Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia

By

Jessica Nye, PhD

Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.

Outcomes for Adolescents With Acute Lymphoblastic Leukemia

By

Vicki Moore, PhD

Clinical trial results indicate that adolescent patients with acute lymphoblastic leukemia have poorer outcomes than younger patients do.

Oral AML Therapy Onureg Gets FDA Approval

By

Brian Park, PharmD

The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.

Prior Use of Novel Agents Does Not Affect alloHCT Outcomes in CLL

By

Andrea S. Blevins Primeau, PhD, MBA

Prior treatment with at least 1 novel agent did not affect allogeneic transplant outcomes among patients with CLL.

Acute lymphoblastic leukemia ALL-L2 blood smear under light microscopy

Risk for Pancreatitis Greater Among Hispanic Children with Acute Lymphoblastic Leukemia

By

Jessica Nye, PhD

Race and ethnicity was a factor in risk for pancreatitis among children with ALL, as was age and presence of obesity and hyperglycemia.

Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.

CLL Diagnosis Preceded by Decades of Increased Infection Susceptibility

By

Katarina Zimmer, MSci, MS

Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.

Nelarabine for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

By

Vicki Moore, PhD

Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.

WT1 Correlates With Survival in Intermediate-, Poor-Risk Acute Myeloid Leukemia

By

Lauren Dembeck, PhD

Investigators aimed to determine the prognostic value of WT1 expression among patients with AML who were in earlier stages of treatment.

Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.

Prior History of SCC Could Be a Red Flag for Development of SCC in the Setting of CLL

By

Susan Moench, PhD, PA-C

In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.

The combination of bendamustine, bortezomib, and dexamethasone was reported to be effective in achie

Genetic Predisposition for Thromboembolism in Adolescent Acute Lymphoblastic Leukemia

By

Lauren Dembeck, PhD

As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.

Older Patients With Previously Untreated AML May Benefit from Azacitidine, Venetoclax

By

Rita Aghjayan

Even after treatment with hypomethylating agents, older patients with AML still lack positive prognoses but azacitidine with venetoclax shows promise.

The overall survival probability was not influenced by their pretransplant level of MRD.

Late Morbidity, Mortality Down for Survivors of Childhood ALL

Compared with 1970s, rate of subsequent malignant neoplasms lower with standard-risk 1990s-like therapy.

Relapse Reduction With Sorafenib in FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic HSCT

By

Rita Aghjayan

Researchers assessed the efficacy and safety of sorafenib maintenance among patients with FLT3-ITD AML who underwent allogeneic HSCT.

Real-World Data Show Temporal Trends in Risk of Serious Bacterial Infections in Patients With CLL

By

Susan Moench, PhD, PA-C

These study findings show the risk and incidence of serious bacterial infection and its effect on mortality for patients with CLL.

Selinexor Produces Responses in HMA-Refractory MDS, Oligoblastic AML

By

Lauren Dembeck, PhD

Selinexor yields responses in patients with MDS or oligoblastic AML refractory to hypomethylating agents, with manageable adverse events.

Incorporating Immunotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia

By

Roxanne Nelson, RN, BSN

Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.

New cancer-specific designs are needed to balance out heart and cancer outcomes in the chronic disease setting of CLL.

Risk-Stratified Therapy Reduces Late Morbidity, Mortality in Pediatric Acute Lymphoblastic Leukemia

By

Jonathan Goodman, MPhil

The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.